Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

Nele Van Der Steen; Christophe Deben; Vanessa Deschoolmeester; An Wouters; Filip Lardon; Christian Rolfo; Paul Germonpré; Elisa Giovannetti; Godefridus J Peters; Patrick Pauwels

doi:10.5306/wjco.v7.i6.425

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

Nele Van Der Steen
, Christophe Deben
, Vanessa Deschoolmeester
, An Wouters
, Filip Lardon
, Christian Rolfo
, Paul Germonpré
, Elisa Giovannetti
, Godefridus J Peters
, Patrick Pauwels

Nele Van Der Steen, Christophe Deben, Vanessa Deschoolmeester, An Wouters, Filip Lardon, Christian Rolfo, Paul Germonpré, Patrick Pauwels, Center for Oncological Research, University of Antwerp, 2610 Wilrijk, Belgium.

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

AIM: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.

METHODS: We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.

RESULTS: All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule.

CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.

Original language	English
Pages (from-to)	425-432
Number of pages	8
Journal	World Journal of Clinical Oncology
Volume	7
Issue number	6
DOIs	https://doi.org/10.5306/wjco.v7.i6.425
Publication status	Published - 10 Dec 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.5306/wjco.v7.i6.425

Cite this

Van Der Steen, N., Deben, C., Deschoolmeester, V., Wouters, A., Lardon, F., Rolfo, C., Germonpré, P., Giovannetti, E., Peters, G. J., & Pauwels, P. (2016). Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. World Journal of Clinical Oncology, 7(6), 425-432. https://doi.org/10.5306/wjco.v7.i6.425

@article{cf6411cd88e94d9abd867b1134545c17,

title = "Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer",

abstract = "AIM: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.METHODS: We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.RESULTS: All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule.CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.",

author = "\{Van Der Steen\}, Nele and Christophe Deben and Vanessa Deschoolmeester and An Wouters and Filip Lardon and Christian Rolfo and Paul Germonpr{\'e} and Elisa Giovannetti and Peters, \{Godefridus J\} and Patrick Pauwels",

year = "2016",

month = dec,

day = "10",

doi = "10.5306/wjco.v7.i6.425",

language = "English",

volume = "7",

pages = "425--432",

journal = "World Journal of Clinical Oncology",

issn = "2218-4333",

publisher = "Baishideng Publishing Group Co",

number = "6",

}

Van Der Steen, N, Deben, C, Deschoolmeester, V, Wouters, A, Lardon, F, Rolfo, C, Germonpré, P, Giovannetti, E , Peters, GJ & Pauwels, P 2016, 'Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer', World Journal of Clinical Oncology, vol. 7, no. 6, pp. 425-432. https://doi.org/10.5306/wjco.v7.i6.425

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. / Van Der Steen, Nele; Deben, Christophe; Deschoolmeester, Vanessa et al.
In: World Journal of Clinical Oncology, Vol. 7, No. 6, 10.12.2016, p. 425-432.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Better to be alone than in bad company

T2 - The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

AU - Van Der Steen, Nele

AU - Deben, Christophe

AU - Deschoolmeester, Vanessa

AU - Wouters, An

AU - Lardon, Filip

AU - Rolfo, Christian

AU - Germonpré, Paul

AU - Giovannetti, Elisa

AU - Peters, Godefridus J

AU - Pauwels, Patrick

PY - 2016/12/10

Y1 - 2016/12/10

N2 - AIM: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.METHODS: We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.RESULTS: All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule.CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.

AB - AIM: To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.METHODS: We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.RESULTS: All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule.CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.

U2 - 10.5306/wjco.v7.i6.425

DO - 10.5306/wjco.v7.i6.425

M3 - Article

SN - 2218-4333

VL - 7

SP - 425

EP - 432

JO - World Journal of Clinical Oncology

JF - World Journal of Clinical Oncology

IS - 6

ER -

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this